- Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
- Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results
- Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
- Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3
- Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences
As of last trade
Arrowhead Pharmaceuticals Inc (ARWR*:MEX) traded at 1,399.00, 0.00% above its 52-week low of 1,399.00, set on Dec 17, 2021.
1,399.00Dec 17 20211,410.00Dec 15 2021
Markit short selling activity
|Market cap||3.12bn USD|
|EPS (TTM)||-1.48 |
Data delayed at least 20 minutes, as of Dec 17 2021 11:30 GMT.